Cancer Medication Price-Fixing Class Action Settlement

UPDATE:

• This class action settlement is paying out up to $1,968 as of July 6, 2022.
• Let Top Class Actions know when you receive a check in the comments section below or on our Facebook page.

A group of cancer patients, their families, and insurers have secured a $55 million class action settlement ending allegations that the maker of Thalomid and Revlimid conspired to keep cheaper, generic versions of the cancer drugs from entering the market.

Class Members include individuals in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, and Tennessee, who paid for the cancer treatment drugs Thalomid or Revlimid before Aug. 1, 2019.

Those who paid for the medication on behalf of another are also eligible.

Additionally, Class Members include insurance companies and other health and welfare companies who paid for or reimbursed individuals for the cancer treatment drugs in those states.

The Thalomid Revlimid antitrust class action alleged that Celgene Corporation withheld generic versions of cancer treatment drugs from the market in order to generate more profit.

The plaintiffs accused the company of forcing cancer patients and their loved ones to pay more for life-saving treatment, even though a generic version of the medication was available.

According to the International Myeloma Foundation, Thalomid is an immunomodulatory drug. This means that the drug affects the immune system and, in conjunction with other medications, is considered an effective treatment for multiple myloma — the first in decades when it was introduced in 2006, according to the Foundation.

Thalomid is thought to be a good alternative to Revlimid, an immune modulator, in patients with low blood cell counts.

Celgene produces both drugs and was hit with a number of lawsuits alleging antitrust behavior by both individual consumers and insurance companies. These Thalomid Revlimid antitrust class action lawsuits were consolidated into multidistrict litigation.

Celgene denies any wrongdoing, but has agreed to pay $55 million to end the Thalomid, Revlimid antitrust class action lawsuit.

Under the terms of the settlement, both individuals and third party payors can make claims. Class Members can claim a part of the settlement amount proportionate to their purchases of either Thalomid or Revlimid.

Both individuals and third party payors must submit a Claim Form either online or via mail. Documentation is not required, but the settlement administrator may ask for proof at a later date.

The deadline for Class Members to object to or opt out of the Thalomid Revlimid antitrust class action settlement is Dec. 2, 2019.

Who’s Eligible

Class Members include both individuals, insurance, and other health and welfare companies who “paid for all or some of the purchase price of Thalomid or Revlimid in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, or Tennessee any time before August 1, 2019.”

Potential Award

Varies. Claims will vary depending on the purchases of the Class Member.

Proof of Purchase

Not required at this time. However, the settlement administrator may ask for proof later on.

Claim Form

CLICK HERE TO FILE A CLAIM »

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

12/30/2019

UPDATE: On December 23, 2019, the court was informed that pursuant to provisions in the settlement agreement, Celgene has decided to terminate the Thalomid and Revlimid Antirust settlement agreement. This means that claims will not be paid at this time. We appreciate your ongoing patience. Top Class Actions will continue to provide updates as we learn more.  

UPDATE 2: July 2020, a revised cancer medications price fixing class action settlement has been reached. Click here to file a claim and to learn more.

Case Name

 In re: Thalomid and Revlimid Antitrust Litigation, Case No. 2:14-cv-06997, in the U.S. District Court for the District of New Jersey

Final Hearing

1/6/2020

Settlement Website

www.ThalomidRevlimidLitigation.com

Claims Administrator

In re Thalomid and Revlimid Antitrust Litigation Settlement Administrator
c/o KCC Class Action Services LLC
PO Box 43143
Providence, RI
02941-3143

info@ThalomidRevlimidLitigation.com

Class Counsel

Melinda R. Coolidge
HAUSFELD LLP

Defense Counsel

John E. Schmidtlein
WILLIAMS & CONNOLLY LLP

Read More Lawsuit & Settlement News:

Chipotle Will Pay $6.5M To Settle GMO Class Action

Diabetes Drugs May Increase Risk of Flesh Eating Disease

PetSmart Class Action Says Hamster Homes Are Defective

Symptoms of Cerebellar Atrophy May Be Caused by Dilantin